Innovative Therapies for Severe Asthma

Total Page:16

File Type:pdf, Size:1020Kb

Innovative Therapies for Severe Asthma Clinical Review Innovative Therapies for Severe Asthma Maj Anna Christensen, MD, USAF; and Michael Ott, MD Severe asthma therapies have progressed to include many options that have improved the quality of life for patients. ore than 39.5 million peo- severity and age group.3 The Inter- mation, therefore, quantifying airway ple in the U.S. have been national European Respiratory So- inflammation.6-8 diagnosed with asthma, ciety (ERS) and American Thoracic There has been some variability and about 3,400 deaths Society (ATS) task force report was in the evidence supporting the use of M 5 occur annually due to asthma com- updated in 2014. The Global Initia- fractional exhaled NO (FeNO) lev- plications.1 Although the prevalence tive for Asthma (GINA) report, up- els as a diagnostic tool. Some stud- of atopy and asthma have increased dated in 2016, now includes several ies have suggested that FeNO is also over the past few decades in west- of the advances in asthma care for elevated in other nonasthma condi- ern countries, control and outcomes those patients refractory to standard tions, such as eosinophilic bronchi- are improving.2 Use of asthma pro- treatments. tis, atopy, and allergic rhinitis. Also, tocols and early recognition by the FeNO levels have been shown to be primary care provider (PCP) are ASTHMA THERAPIES variably influenced by smoking, bron- among the main reasons for trends In this review, the authors cover choconstriction, and viral respiratory toward decreased hospitalization therapies for severe asthma that are infections.9 However, FeNO levels and fewer asthma-related deaths.3,4 becoming more important for PCPs > 50 ppb correlated most strongly In addition to the mainstay of to consider, including exhaled nitric with eosinophilic asthma and steroid treatments, including trigger avoid- oxide (NO) levels, the use of tiotro- responsiveness.9 ance, inhaled corticosteroids (ICS), pium for asthma, the applicability of Fractional exhaled NO tests now and rescue bronchodilators, new biologic agents, the use of allergen can be performed in the PCP of- therapies have been developed to immunotherapy, and the usefulness fice with NIOX VERO (Chicago, supplement the treatment of severe of roflumilast. This review also cov- IL), a small, relatively inexpensive persistent asthma, which constitutes ers antileukotriene therapy, bronchial device. Although the 2016 GINA about 5% to 10% of asthma cases. Se- thermoplasty, and a discussion of long- guidelines and the 2015 ERS/ATS vere asthma is defined as asthma that acting beta-agonist (LABA) therapy. guidelines do not offer specific rec- is unresponsive to baseline therapy.5 ommendations for use and do not Three sets of guidelines and rec- Fractional Exhaled Nitric Oxide support withholding ICS based on ommendations exist to provide Nitric oxide is present in the exhaled FeNO test results, guidelines for structure to asthma treatment deci- breath and is elevated in those with FeNO use do exist. In 2011, ATS sion making. The Expert Panel Re- eosinophilic asthma.6 The role of NO published a specific set of FeNO port-3 (EPR-3) was created by the in asthma pathology is complex, in- interpretive guidelines for office- National Education and Prevention volving proinflammatory qualities based use.9 When performed in Program (NAEPP) and was last pub- that contribute to airway hyperre- conjunction with standard testing, lished in 2007. The NAEPP favors a sponsiveness (AHR) and as a weak FeNO levels can provide valuable stepwise approach, based on asthma mediator of smooth muscle relax- clinically relevant information, such ation. In exhaled air, NO correlates as (1) detection of eosinophilic air- Maj Christensen and Dr. Ott are physicians at with up-regulation of NO synthase way inflammation; (2) determin- Eglin Air Force Hospital in Valparasio, Florida. (NOS), which occurs with inflam- ing the likelihood of corticosteroid www.fedprac.com DECEMBER 2017 • FEDERAL PRACTITIONER • 25 ASTHMA THERAPIES Table 1. FeNO Interpretation9 Diagnosis Monitoring Levels Symptoms Present Symptoms Present Symptoms Absent FeNO < 25 ppb Eosinophilic airway inflammation unlikelya Check alternative diagnoses, unlikely Adequate ICS dose (< 20 ppb for patients < 12 y) Unlikely to benefit from ICSa to benefit from increase in ICS Consider taper FeNO 25-50 ppb Be cautious, evaluate clinical symptoms Inadequate ICS dose, consider Adequate ICS dose (20-35 ppb for patients < 12 y) and FENO over timeb steroid resistance or poor adherence Persistent allergen exposure FeNO > 50 ppb Eosinophilic airway inflammation presenta Inadequate ICS dose, steroid ICS taper may result (> 35 ppb for patients < 12 y) Likely to benefit from ICSa resistance or poor adherence; in relapse increased risk for exacerbation Poor adherence or Persistent allergen response technique Abbreviations: FeNO, fraction of exhaled nitric oxide; ICS, inhaled corticosteroid; PPB, parts per billion. aStrong recommendation, moderate quality of evidence. bStrong recommendation, low quality of evidence. responsiveness; (3) monitoring of The FDA approved the addition exertional dyspnea and exercise tol- airway inflammation to determine of tiotropium for treating asthma erance. On day 42 of a randomized, the need for steroids; and (4) un- in September 2015 for patients double-blinded, placebo-controlled, masking of otherwise unsuspected aged ≥ 12 years. The use of tiotro- parallel-group study of 187 patients, nonadherence to corticosteroid pium is supported by both the ERS/ vital capacity and inspiratory capac- therapy (Table 1). ASTS and GINA 2016 guidelines. ity were noted to be increased with The recommended and approved decreases in residual volume and Tiotropium as an Adjunct Treatment dose of tiotropium for asthma is functional residual capacity. Exercise Tiotropium is a long-acting inhaled 2.5 µg daily (the recommended endurance times increased by 105 ± anticholinergic. A sentinel 1984 study dose for COPD treatment is 5 µg).12 40 sec (21%).16 This effect has not by Gross and Skorodin demonstrated A recent phase 3 study compared been studied yet in a population of that parasympathetic activity is the 2.5 µg vs 5 µg dosing with ICS but patients with asthma; however, the dominant reversible component in no LABA in adolescents, noting sig- same principles may hold true. patients with chronic obstructive pul- nificant improvement with the 2.5 µg monary disease (COPD), including dose.13 Adding tiotropium to ICS + BIOLOGIC AGENTS emphysema.10 In addition, all achiev- LABA in patients with severe symp- Recent asthma research has been fo- able bronchodilation was obtained tomatic asthma has been associated cused on disrupting the inflamma- with an inhaled anticholinergic com- with positive results in initial studies tory cascade. Both GINA and ERS/ pared with that of separate or simul- by Kersjens and colleagues.14 Even ATS divide asthma into allergic taneous administration of adrenergics. as early as 2010, the use of tiotro- vs nonallergic endotypes. Allergic Sympathetic neural pathways are pium was shown to produce statis- asthma usually is manifested by spu- sparse in human lungs and have their tically significant improvement in tum eosinophilia and high serum endings on the cells of the cholinergic morning peak expiratory flow (PEF), eosinophil counts, whereas other postganglionic fibers, because sym- with a mean difference of 25.8 L/min endotypes include aspirin-sensitive pathetic terminals on airway smooth (n = 210, P < .001).15 and exercise-induced asthmas that muscle cells are rare or nonexistent.11 Tiotropium also has been shown to present with a neutrophilic predomi- Therefore, sympathetic modulation or provide a sustained reduction in lung nance. Nonallergic asthma is more activation of beta cells could change hyperinflation for those with COPD, severe typically and has been linked the parasympathetic tone.11 thus providing an improvement in to steroid resistance.17 Many different 26 • FEDERAL PRACTITIONER • DECEMBER 2017 www.fedprac.com ASTHMA THERAPIES Table 2. Biologic Agents for the Treatment of Severe Asthma20,23,26,30,34-39 Treatment (Brand) Mechanism of Action Type of Antibody Approved for Use (y) Omalizumab (Xolair) Antibody that creates inert IgE complexes and stops Humanized MAB Yes (2003) complement activation Mepolizumab (Nucala) Binds directly to IL-5 and prevents eosinophil activation Humanized MAB Yes (2015) Reslizumab (Cinqair) Binds directly to IL-5 and prevents eosinophil activation Humanized MAB Yes (2016) Dupilumab Binds to the IL-4Rα subunit of the IL-4 receptor, blocks Human MAB No, but received FDA “break- Th2 activation through therapy” designation Fevipiprant Prostaglandin D2 receptor antagonist, blocks migration of N/A No Th2 cells, cytokines, prevents eosinophil activation Benralizumab Anti-IL-5 receptor, block eosinophil activation Humanized MAB No Abbreviations: IG, immunoglobulin; IL, interleuken; MAB, monoclonal antibody, Th2, T helper type 2. phenotypes have been identified, the newer completely human MABs. analysis of more than 10,000 patients but the main categories include eo- Omalizumab forms small, biologically did not support any relationship with sinophilic, neutrophilic, mixed, and inert IgE+ anti-IgE complexes that malignancy.27,28 A higher incidence paucigranulocytic.18 cannot activate the complement cas- of cardiovascular and cerebrovascu- Mast cells, bronchial epithelium, cade. The serum free IgE level is de- lar AEs has been observed, and the and macrophages are involved in creased.20 Approved in 2003
Recommended publications
  • Japanese Guidelines for Adult Asthma 2020*
    Allergology International xxx (xxxx) xxx Contents lists available at ScienceDirect Allergology International journal homepage: http://www.elsevier.com/locate/alit Invited Review Article Japanese guidelines for adult asthma 2020* * Yoichi Nakamura a, , Jun Tamaoki b, Hiroyuki Nagase c, Masao Yamaguchi d, Takahiko Horiguchi e, Soichiro Hozawa f, Masakazu Ichinose g, Takashi Iwanaga h, Rieko Kondo e, Makoto Nagata i, Akihito Yokoyama j, Yuji Tohda h, The Japanese Society of Allergology a Medical Center for Allergic and Immune Diseases, Yokohama City Minato Red Cross Hospital, Yokohama, Japan b First Department of Medicine, Tokyo Women's Medical University, Tokyo, Japan c Division of Respiratory Medicine and Allergology, Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan d Third Department of Medicine, Teikyo University Chiba Medical Center, Chiba, Japan e Department of Respiratory Medicine, Fujita Health University Bantane Hospital, Nagoya, Japan f Hiroshima Allergy and Respiratory Clinic, Hiroshima, Japan g Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan h Department of Respiratory Medicine and Allergology, Kinki University Faculty of Medicine, Osaka, Japan i Department of Respiratory Medicine, Saitama Medical University Hospital, Saitama, Japan j Department of Hematology and Respiratory Medicine, Kochi University, Kochi, Japan article info abstract Article history: Bronchial asthma is characterized by chronic airway inflammation, which manifests clinically as variable Received 9 June 2020 airway narrowing (wheezes and dyspnea) and cough. Long-standing asthma may induce airway Available online xxx remodeling and become intractable. The prevalence of asthma has increased; however, the number of patients who die from it has decreased (1.3 per 100,000 patients in 2018).
    [Show full text]
  • Improved Homology Modeling of the Human & Rat EP4 Prostanoid Receptors
    Holt et al. BMC Molecular and Cell Biology (2019) 20:37 BMC Molecular and https://doi.org/10.1186/s12860-019-0212-5 Cell Biology RESEARCHARTICLE Open Access Improved homology modeling of the human & rat EP4 prostanoid receptors Melissa C. Holt, Chi S. Ho, M. Inés Morano, Stephen D. Barrett and Adam J. Stein* Abstract Background: The EP4 prostanoid receptor is one of four GPCRs that mediate the diverse actions of prostaglandin E2 (PGE2). Novel selective EP4 receptor agonists would assist to further elucidate receptor sub-type function and promote development of therapeutics for bone healing, heart failure, and other receptor associated conditions. The rat EP4 (rEP4) receptor has been used as a surrogate for the human EP4 (hEP4) receptor in multiple SAR studies. To better understand the validity of this traditional approach, homology models were generated by threading for both receptors using the RaptorX server. These models were fit to an implicit membrane using the PPM server and OPM database with refinement of intra and extracellular loops by Prime (Schrödinger). To understand the interaction between the receptors and known agonists, induced-fit docking experiments were performed using Glide and Prime (Schrödinger), with both endogenous agonists and receptor sub-type selective, small-molecule agonists. The docking scores and observed interactions were compared with radioligand displacement experiments and receptor (rat & human) activation assays monitoring cAMP. Results: Rank-ordering of in silico compound docking scores aligned well with in vitro activity assay EC50 and radioligand binding Ki. We observed variations between rat and human EP4 binding pockets that have implications in future small-molecule receptor-modulator design and SAR, specifically a S103G mutation within the rEP4 receptor.
    [Show full text]
  • Q4 2019/20 Initiation
    Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date of Date Site Date Site Reasons Participan Confirme HRA Date Site Non- Date Site Committe Research Name of First Selected Selected Date Site Date Site Date Site for delay t d and Approval Confirmed Confirmat Ready To e Applicatio Trial Participant and Date and First Invited Selected Confirmed correspon Recruited First Date By Sponsor ion Status Start Reference n System Recruited Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited VIVOTM non- invasive mapping 19/LO/03 Please Please 162140 257755 of Yes 03/07/2019 26 33 59 01/03/2019 05/05/2019 21/04/2019 15/05/2019 31/05/2019 31/05/2019 08 Select... Select... ventricula r arrhythmi a A Pilot Study to exPlOre the exisTence and impact of 19/LO/07 FRAILTY Please Please 162141 264744 Yes 20/08/2019 31 11 42 01/04/2019 09/07/2019 16/07/2019 24/07/2019 09/08/2019 09/08/2019 84 in Select... Select... patients over the age of 70 undergoin g cardiac interventi ons Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date of Date Site Date Site Reasons Participan Confirme HRA Date Site Non- Date Site Committe Research Name of First Selected Selected Date Site Date Site Date Site for delay t d and Approval Confirmed Confirmat Ready To e Applicatio Trial Participant and Date and First Invited Selected Confirmed correspon Recruited First Date By Sponsor ion Status Start Reference n System Recruited Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited "Pressure- controlled Intermitte nt Coronary Sinus 19/SC/00 Occlusion Please Please 162142 259683 Yes 23/09/2019 40 12 52 01/04/2019 02/08/2019 16/07/2019 14/08/2019 11/09/2019 16/09/2019 50 (PiCSO) in Select..
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Investigational Allergology and Clinical Immunology
    Journal of Investigational Allergology and Clinical Immunology ISSN 1018-9068 Volume 31, Supplement 1, 2021 Official Organ of Spanish Society of Allergology and Clinical Immunology www.jiaci.org GEMA5.0 SPANISH GUIDELINE ON THE MANAGEMENT OF ASTHMA Journal of Investigational Allergology and Clinical Immunology Volume 31, Suppl. 1, 2021 Official Organ of Spanish Society of Allergology and Clinical Immunology Editors in Chief A.G. Oehling, Servicio de Alergología, Clínica Rotger, C/ Santiago Rusiñol 3, E-07012 Palma de Mallorca, Spain (E-mail [email protected]) J.M. Olaguibel, Unidad de Asma Grave, Servicio de Alergología, Complejo Hospitalario de Navarra, C/Irunlarrea s/n, E-31008 Pamplona, Spain (Tel. +34 948 255-400, Fax +34 948 296-500, E-mail [email protected]) Associate Editors I. Dávila, Hospital Clínico Universitario, Paseo San Vicente s/n, E-37007 Salamanca, Spain P.M. Gamboa, Servicio de Alergología, Hospital de Cruces, Plaza de Cruces, s/n, E-48903 Baracaldo, Bizkaia, Spain R. Lockey, University of South Florida College of Medicine, Division of Allergy and Immunology, VA Medical Center, 13000 North 30th Street, Tampa, FL 33612, USA V. del Pozo, Senior Research, Immunology IIS-FJD, Avda. Reyes Católicos 2, E-28040 Madrid, Spain J. Sastre, Servicio de Alergia, Fundación Jiménez Díaz, Avda. Reyes Católicos 2, E-28040 Madrid, Spain J.M. Zubeldia, Servicio de Alergología, Hospital G.U. Gregorio Marañón, C/ Dr. Esquerdo 46, E-28007 Madrid, Spain Founding Editor A.K. Oehling †, Department of Allergology and Clinical Immunology, Clínica Universidad de Navarra, Apartado 4209, E-31008 Pamplona, Spain Editorial Assistant G. Betelu, Department of Allergology and Clinical Immunology, Clínica Universidad de Navarra, Apartado 4209, E-31008 Pamplona, Spain (Tel.
    [Show full text]
  • PDCO Minutes of the 20-23 February 2018 Meeting
    23 February 2018 EMA/PDCO/113780/2018 Inspections, Human Medicines Pharmacovigilance and Committees Division Paediatric Committee (PDCO) Minutes of the meeting on 20-23 February 2018 Chair: Dirk Mentzer – Vice-Chair: Koenraad Norga 20 February 2018, 14:00- 17:00, room 3A 21 February 2018, 08:30- 19:00, room 3A 22 February 2018, 08:30- 19:00, room 3A 23 February 2018, 08:30- 13:00, room 3A Disclaimers Some of the information contained in this set of minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the PDCO Committee meeting reports (after the PDCO Opinion is adopted), and on the Opinions and decisions on paediatric investigation plans webpage (after the EMA Decision is issued). Of note, this set of minutes is a working document primarily designed for PDCO members and the work the Committee undertakes. Further information with relevant explanatory notes can be found at the end of this document. Note on access to documents Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).
    [Show full text]
  • Structures of the Human PGD2 Receptor CRTH2 Reveal Novel Mechanisms for Ligand Recognition
    Article Structures of the Human PGD2 Receptor CRTH2 Reveal Novel Mechanisms for Ligand Recognition Graphical Abstract Authors Lei Wang, Dandan Yao, R.N.V. Krishna Deepak, ..., Weimin Gong, Zhiyi Wei, Cheng Zhang Correspondence [email protected] (Z.W.), [email protected] (C.Z.) In Brief Wang et al. reported crystal structures of antagonist-bound human CRTH2 as a new asthma drug target. Chemically diverse antagonists occupy a similar semi-occluded pocket with distinct binding modes. Structural analysis suggests a potential ligand entry port and an opposite charge attraction-facilitated binding process for the endogenous CRTH2 ligand prostaglandin D2. Highlights d Crystal structures of antagonist-bound human CRTH2 are solved d A well-structured N terminus covers ligand binding pocket d Conserved and divergent binding features of CRTH2 antagonists are revealed d A multiple-step binding process of prostaglandin D2 is proposed Wang et al., 2018, Molecular Cell 72, 48–59 October 4, 2018 ª 2018 Elsevier Inc. https://doi.org/10.1016/j.molcel.2018.08.009 Molecular Cell Article Structures of the Human PGD2 Receptor CRTH2 Reveal Novel Mechanisms for Ligand Recognition Lei Wang,1,7 Dandan Yao,2,3,7 R.N.V. Krishna Deepak,4 Heng Liu,1 Qingpin Xiao,1,5 Hao Fan,4 Weimin Gong,2,6 Zhiyi Wei,5,* and Cheng Zhang1,8,* 1Department of Pharmacology and Chemical Biology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15261, USA 2Key Laboratory of RNA Biology, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China 3University
    [Show full text]
  • (CRTH2) Antagonists in Asthma: a Systematic Review and Meta-Analysis Protocol AUTHORS Liu, Wei; Min, Jie; Jiang, Hongli; Mao, Bing
    BMJ Open: first published as 10.1136/bmjopen-2017-020882 on 20 April 2018. Downloaded from PEER REVIEW HISTORY BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf) and are provided with free text boxes to elaborate on their assessment. These free text comments are reproduced below. ARTICLE DETAILS TITLE (PROVISIONAL) Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTH2) antagonists in asthma: a systematic review and meta-analysis protocol AUTHORS liu, wei; Min, Jie; Jiang, Hongli; Mao, Bing VERSION 1 – REVIEW REVIEWER Hugo Farne Imperial College London United Kingdom REVIEW RETURNED 05-Jan-2018 GENERAL COMMENTS This is an interesting proposal as the findings have indeed been contradictory. My major comment is about the language - this paper would benefit significantly from proof-reading by a native English speaker (e.g. first para page 8). http://bmjopen.bmj.com/ Other comments: Strengths & Limitations (p5): - As there are no head-to-head trials of CRTH2 antagonists, subgroup analyses cannot directly assess the efficacy of CRTH2 antagonists relative to each other - By having no cut-off in terms of minimum duration of treatment (e.g. 12 weeks or 16 weeks), the study may include trials on September 28, 2021 by guest. Protected copyright. that were underpowered, which in turn may dilute any effect – I would note this. Introduction (p7) - CRTH2 is also expressed on Type 2 Innate Lymphoid Cells (ILC2s) - CRTH2 is not expressed on mast cells (except intracellularly, with unknown function) so production of cytokines from mast cells is not a consequence of PGD2 binding to CRTH2 on mast cells - The rationale for the CRTH2 receptor as a drug target in asthma is not explained fully.
    [Show full text]
  • Fevipiprant (QAW039), a Slowly Dissociating Crth2 Antagonist with the Potential for Improved Clinical Efficacy S
    Supplemental material to this article can be found at: http://molpharm.aspetjournals.org/content/suppl/2016/02/25/mol.115.101832.DC1 1521-0111/89/5/593–605$25.00 http://dx.doi.org/10.1124/mol.115.101832 MOLECULAR PHARMACOLOGY Mol Pharmacol 89:593–605, May 2016 Copyright ª 2016 by The American Society for Pharmacology and Experimental Therapeutics Fevipiprant (QAW039), a Slowly Dissociating CRTh2 Antagonist with the Potential for Improved Clinical Efficacy s David A. Sykes, Michelle E. Bradley, Darren M. Riddy, Elizabeth Willard, John Reilly, Asadh Miah, Carsten Bauer, Simon J. Watson, David A. Sandham, Gerald Dubois, and Steven J. Charlton Novartis Institutes for Biomedical Research, Horsham, West Sussex, UK (D.A.S., M.E.B., D.M.R., E.W., J.R., A.M., S.W., D.A.S., G.D., S.J.C.); Novartis Institutes for Biomedical Research, Cambridge, Massachusetts (D.A.Sa., J.R.); Novartis Institutes for Biomedical Research, Basel, Switzerland (C.B.); School of Life Sciences, Queen’s Medical Centre, University of Nottingham, Downloaded from Nottingham, UK (D.A.Sy., S.J.C.) Received September 22, 2015; accepted February 22, 2016 ABSTRACT Here we describe the pharmacologic properties of a series of reversed by increasing concentrations of PGD2 after an initial molpharm.aspetjournals.org clinically relevant chemoattractant receptor-homologous mole- 15-minute incubation period. This behavior is consistent with cules expressed on T-helper type 2 (CRTh2) receptor antago- its relatively slow dissociation from the human CRTh2 receptor. nists, including fevipiprant (NVP-QAW039 or QAW039), which is In contrast for the other ligands tested this time-dependent currently in development for the treatment of allergic diseases.
    [Show full text]
  • Data on the Oral Crth2 Antagonist QAW039 (Fevipiprant) in Patients with Uncontrolled Allergic Asthma
    Data in Brief 9 (2016) 199–205 Contents lists available at ScienceDirect Data in Brief journal homepage: www.elsevier.com/locate/dib Data Article Data on the oral CRTh2 antagonist QAW039 (fevipiprant) in patients with uncontrolled allergic asthma Veit J. Erpenbeck a,n, Todor A. Popov b, David Miller c, Steven F. Weinstein d, Sheldon Spector e, Baldur Magnusson a, Wande Osuntokun f, Paul Goldsmith f, Markus Weiss a, Jutta Beier g a Novartis Pharma AG, Basel, Switzerland b Clinic of Allergy & Asthma, Medical University Sofia, Sofia, Bulgaria c NEMRA, North Dartmouth, MA, United States d Allergy & Immunology, Allergy and Asthma Specialists Medical Group and Research Center, CA, United States e Allergy & Asthma, California Allergy and Asthma Medical Group Inc, CA, United States f Novartis Pharmaceuticals, Horsham, United Kingdom g INSAF, Respiratory Research Institute GmbH, Wiesbaden, Germany article info abstract Article history: This article contains data on clinical endpoints (Peak Flow Expiratory Received 21 June 2016 Rate, fractional exhaled nitric oxide and total IgE serum levels) and Received in revised form plasma pharmacokinetic parameters concerning the use of the oral 10 August 2016 CRTh2 antagonist QAW039 (fevipiprant) in mild to moderate asthma Accepted 19 August 2016 patients. Information on experimental design and methods on how Available online 29 August 2016 this data was obtained is also described. Further interpretation and discussion of this data can be found in the article “The oral CRTh2 antagonist QAW039 (fevipiprant): a phase II study in uncontrolled allergic asthma” (Erpenbeck et al., in press) [1]. & 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Risk Assessment of Reactive Metabolites in Drug Discovery: a Focus on Acyl Glucuronides and Acyl-Coa Thioesters
    Risk Assessment of Reactive Metabolites in Drug Discovery: A Focus on Acyl Glucuronides and Acyl-CoA Thioesters The Delaware Valley Drug Metabolism Discussion Group 2017 Rozman Symposium HUMAN BIOTRANSFORMATION: THROUGH THE MIST Langhorne, PA, June 13, 2017 Mark Grillo, PhD Drug Metabolism & Pharmacokinetics MyoKardia South San Francisco, CA [email protected] CommercializationDrug Process Discovery Overview & Development Therapeutic Area/Disease Lead Selection & Product Strategy Market Readiness & Launch / Post-Launch Opportunity Assessment Pre-clinical Testing Development Regulatory Approval Lifecycle Management Hit-to- Lead Post- Discovery Screen Pre-clinical Phase 1 Phase 2 Phase 3 Filing Launch Lead Optimization Launch Preclinical Pharmacokinetics & Drug Metabolism Assays Target Selection & Validation Lead compound Selection Discovery Screen Hit-to-Lead Lead Optimization Optimize Pharmacokinetics Characterize Preclinical Candidate Liver microsomal stability Intrinsic clearance Membrane permeability Excretion balance Efflux/transport assays Definitive metabolite ID Plasma stability Higher species PK Rat PK Human PK prediction Protein binding Assess DDI Potential Blood to plasma ratio Competitive CYP IC50 Early DDI Assessment Time-dependent CYP inhibition Enzyme induction PXR activation Hepatocyte induction CYP inhibition CYP reaction phenotyping Detection and Assessment of Chemically-Reactive Metabolites 2 Circumstantial Evidence Links Reactive Metabolites to Adverse Drug Reactions • Toxicity is a frequent cause of drug withdrawal
    [Show full text]